Effect of a platelet-activating factor (PAF) receptor antagonist on hyperacute xenograft rejection; Evaluation in a pig kidney-human blood xenoperfusion model

Clinical and Experimental Immunology

Volumn 113, Issue 1, 1998, Pages 136-144

  Cruzado, J M ^a   Torras, J ^a   Riera, M ^a   Lloberas, N ^a   Herrero, I ^a   Condom, E ^a   Martorell, J ^b   Alsina, J ^a   Grinyo J M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Human blood; Hyperacute xenograft rejection; Pig kidney; Platelet activating factor; Platelet activating factor antagonist; Xenoperfusion

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; GINKGOLIDE B; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYELOPEROXIDASE; PADGEM PROTEIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HUMAN; HUMAN CELL; KIDNEY PERFUSION; MALE; MICROTHROMBUS; NONHUMAN; PRIORITY JOURNAL; SWINE; XENOTRANSPLANTATION;

ANIMALS; DITERPENES; FIBRINOLYTIC AGENTS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GINKGOLIDES; GRAFT REJECTION; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LACTONES; MALE; P-SELECTIN; PERFUSION; PEROXIDASE; PLATELET ACTIVATING FACTOR; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031820999     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00634.x     Document Type: Article

References (43)

1. Platt JL, Vercellotti GM, Dalmasso AP et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11:450-6.
2. Parker W, Saadi S, Lin SS, Holzknecht ZE, Bustos M, Platt JL. Transplantation of discordant xenografts: a challenge revisited. Immunol Today 1996; 17:373-8.
3. Sandrin MS, Fodor WL, Mouhtouris E et al. Enzymatic remodeling of the carbohydrate surface of a xenogenic cell subtantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1995; 1:1261-7.
4. Sharma A, Okabe J, Birch P et al. Reduction in the level of Gal(alphal,3)Gal in transgenic mice and pigs by the expression of an alphad(1, 2)fucosyltransferase. Proc Natl Acad Sci USA 1996; 93:7190-5.
5. Cozzi E, White D. The generation of transgenic pigs as potential donors for humans. Nat Med 1995; 1:964-6.
6. Ryan US. Complement inhibitory therapeutics and xenotransplantation. Nat Med 1995; 1:967-8.
7. Bach FH, Winkler H, Ferran C, Hancock WW, Robson SC. Delayed xenograft rejection. Immunol Today 1996; 17:379-84.
8. Imaizumi TA, Stafforini DM, Yamada Y, Mcintyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians. J Int Med 1995; 238:5-20.
9. Zimmerman GA, Prescott SM, Mcintyre TM. Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today 1992; 13:93-100.
10. Hattori R, Hamilton KK, Fugate RD, McEver RP, Sims PJ. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem 1989; 264:7768-71.
11. Patel KD, Zimmerman GA. Prescott SM et al. Oxygen radicals induce human endothelial cells to express GMP-140 and hind neutrophils. J Cell Biol 1991; 112:749-59.
12. Lorant DE, Topham MK, Whatley RE et al. Inflammatory roles of P-selectin. J Clin Invest 1993; 92:559-70.
13. Bussolino F, Camussi G, Aglietta M et al. Human endothelial cells are target for platelet activating factor. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol 1987; 139:2439-46.
14. Camussi G, Niesen N, Tetta C, Saunders RN, Milgrom F. Release of platelet-activating factor from rabbit heart perfused in vitro by sera with transplantation alloantibodies. Transplantation 1987; 44:113-8.
15. Makowka L, Chapman FA, Cramer DV, Qian S, Sun H, Starzl TE. Platelet-activating factor and hyperacute rejection. Transplantation 1990; 50:359-65.
16. Coughlan AF, Berndt MC, Dunlop LC, Hancock WW. In vivo studies of P-selectin and platelet activating factor during endotoxemia. accelerated allograft rejection, and discordant xenograft rejection. Transplant Proc 1993; 25:2930-1.
17. O'Hair DP, Roza AM, Pieper GM et al. Platelet activating factor antagonist RP-59227 reduces vascular injury in discordant cardiac xenograft rejection. Transplant Proc 1992; 24:702-3.
18. Boillot O, Patrzalek D. Cardoso J et al. Delay of xenogeneic hyperacute rejection by BN 52021 in a model of rabbit to pig liver transplantation. Transplant Proc 1996; 28:767.
19. Saumweber DM, Bergmann R, Gokkel M, Hammer C. Hyperacute rejection in an ex vivo model of renal xenografting. Transplantation 1994; 57:358-63.
20. Taniguchi S, Kitamura S, Kawachi K, Fukutomi M, Yoshida Y. Effects of a platelet-activating factor antagonist at different doses given simultaneously with double-filtration plasmapheresis on cardiac xenograft survival. Transplant Proc 1994; 26:969-71.
21. Makowka L, Miller C, Chapchap P et al. Prolongation of pig to dog renal xenograft by modification of the infammatory mediator response. Ann Surg 1987; 206:482-95.
22. Otte KE, Jorgensen KA, Bonnevie V et al. Xenoperfusion of rabbit kidney and the impact of BN 52021: a specific antagonist of platelet-activating factor. Transplant Proc 1990; 22:1089-90.
23. Suckfüll MM, Pieske O, Müdsam M, Babic R, Hammer C. The contribution of endothelial cells to hyperacute rejection in xenogeneic perfused working hearts. Transplantation 1994; 57:262-7.
24. Herrero I, Torras J, Carrera M et al. Evaluation of a preservation solution containing fructose-1.6-diphosphate and mannitol using the isolated prefused rat kidney. Nephrol Dial Transpl 1995; 10:519-26.
25. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37:911-7.
26. Ferraris L, Karmeli F, Eliakim R, Klein J, Fiocchi C, Rachmilewitz D. Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis. Gut 1993; 34:665-8.
27. Bradley PP, Priebat DA, Christensen RD, Rothstein RD. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78:206-9.
28. Riera M, Torras J, Herrero I et al. Neutrophils accentuate renal cold ischemia-reperfusion injury. Dose-dependent protective effect of a platelet-activating factor receptor antagonist. J Pharmacol Exp Ther 1997; 280:786-94.
29. Grinyo IM, Cruzado JM, Riera M et al. Functional and pathologic outcome after complement inactivation in a pig kidney-human blood xenoperfusion model. Transplant Proc 1997; 29:2318-21.
30. Butterly DW, Spurney RF, Ruiz P, Pirotzky E, Braquet P, Cofftman TM. Role of platelet activating factor in kidney transplant rejection in the rat. Kidney Int 1995;48:337-43.
31. Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood 1989; 73:1109-12.
32. Johnston GI, Cook RG, McEver RP. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell 1989; 56:1033-44.
33. Blann AD, Lip GYH. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 1997; 128:135-8.
34. Foreman KE, Vaporciyan AA, Bonish BK et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994; 94:1147-55.
35. Peerschke EIB, Reid KBM, Ghebrehiwet B. Platelet activation by Clq results in the induction of alpha lib/beta 3 integrins (GP IIb-IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med 1993; 178:579-87.
36. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-C9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264:9053-60.
37. Korth R, Hirafuji M, Lalau Keraly C, Delautier D, Bidault J, Benveniste J. Interaction of the antagonist WEB 2086 and its hetrazepine analogue with human platelets and endothelial cells. Br J Pharmacol 1989; 98:653-61.
38. Lerner R, Lindstrom P, Palmblad J. Platelet-activating factor and leukotriene B4 induce hyperpolarization of human endothelial cells but depolarization of neutrophils. Biochem Biophys Res Commun 1988; 153:805-10.
39. Camussi G, Turello E, Bussolino F, Baglioni C. Tumor necrosis factor alters cytoskeletal organization and barrier function of endothelial cells. Int Arch Allergy Appl Immunol 1991; 96:84-91.
40. Chao W, Olson MS. Platelet-activating factor: receptor and signal transduction. Biochem J 1993; 292:617-29.
41. Camussi G, Montrucchio G, Lupia E et al. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol 1995; 154:6492-501.
42. Saadi S, Platt JL. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med 1995; 181:21-31.
43. Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI. von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest 1991; 88:1568-73.